title: Decreased cytotoxic activity of natural killer cells in kidney allograft recipients treated with human HLA-derived peptide.
abstract: Peptides derived from a conserved region (aa 75-84) of HLA class I, overlapping the supertypic HLA-BW4/BW6 antigen region, have been shown to exhibit nonallele restricted immunosuppressive properties in rats and mice, prolonging survival of major histocompatibility complex-mismatched allografts. Furthermore, HLA-B7 peptides inhibit alloreactive cytotoxic cells, and both HLA-B7 and HLA-B2702 peptides inhibit natural killer (NK) cytotoxicity in vivo. In this article, we report on a randomized, controlled study of the safety and pharmacokinetics of HLA-B2702-derived peptide in human recipients of a first kidney allograft. Escalating doses of HLA-B2702 were compared with doses of placebo controls. No toxicity and no immunization against the peptide were noted. Although the study was not designed as an efficacy trial, patients who received the high-dose protocol (7 mg/kg) did experience more rejection episodes, but this was not statistically significant when compared with control patients. Interestingly, in human recipients, as previously observed in rodents, administration of the peptide was associated with a statistically significant decrease in the cytotoxicity of NK cells against K562 targets (P<0.001). As these peptides correspond to a region of the HLA class I molecule that interacts with the newly described NK receptors for class I, their mode of action through interaction with such receptors is discussed. As a peptide of the same sequence from HLA-B7 blocks both NK and alloreactive T cell cytotoxicity, it is possible that, in humans too, both types of cytotoxic cells are affected by this peptide. The biological significance of these observations should be confirmed in future controlled studies with a larger patient population.
authors.affiliation: Institut de Transplantation et de Recherche en Transplantation (ITERT), Centre Hospitalier Universitaire, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Giral
authors.forename: M C
authors.initials: MC
authors.lastname: Cuturi
authors.forename: J M
authors.initials: JM
authors.lastname: Nguyen
authors.forename: R
authors.initials: R
authors.lastname: Josien
authors.forename: J
authors.initials: J
authors.lastname: Dantal
authors.forename: R
authors.initials: R
authors.lastname: Floc'h
authors.forename: R
authors.initials: R
authors.lastname: Buelow
authors.forename: P
authors.initials: P
authors.lastname: Pouletty
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D015395:Histocompatibility Antigens Class I / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans; D007239:Infections / Q000453:epidemiology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000009:adverse effects* / Q000493:pharmacokinetics
chemical_list: D000961:Antilymphocyte Serum; D015395:Histocompatibility Antigens Class I; D010455:Peptides; C092373:allotrap